The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
Abstract
Purpose: To describe the clinical, radiologic, and pathologic features and risk factors for osteonecrosis of the jaw (ONJ) in multiple myeloma (MM) patients. Patients and Methods: A retrospective review of 90 MM patients who had dental assessments, including 22 patients with ONJ. There were 62 men; the median age was 61 years in ONJ patients and 58 years among the rest. Prior MM therapy included thalidomide (n = 67) and stem-cell transplantation (n = 72). Bisphosphonate therapy included zoledronate (n = 34) or pamidronate (n = 17) and pamidronate followed by zoledronate (n = 33). Twenty-seven patients had recent dental extraction, including 12 patients in the ONJ group. Median time from MM diagnosis to ONJ was 8.4 years for the whole group. Results: Patients usually presented with pain. ONJ occurred posterior to the cuspids (n = 20) mostly in the mandible. Debridement and sequestrectomy with primary closure were performed in 14 patients; of these, four patients had major infections and four patients had recurrent ONJ. Bone histology revealed necrosis and osteomyelitis. Microbiology showed actinomycetes (n = 7) and mixed bacteria (n = 9). More than a third of ONJ patients also suffered from long bone fractures (n = 4) and/or avascular necrosis of the hip (n = 4). The variables predictive of developing ONJ were dental extraction (P = .009), treatment with pamidronate/zoledronate (P = .009), longer follow-up time (P = .03), and older age at diagnosis of MM (P = .006). Conclusion: ONJ appears to be time-dependent with higher risk after long-term use of bisphosphonates in older MM patients often after dental extractions. No satisfactory therapy is currently available. Trials addressing the benefits/risks of continuing bisphosphonate therapy are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.
Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J. M., Castronovo, V., & Green, J. R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035295 · Cited by 854
Osteonecrosis of the Jaw and Bisphosphonates
(2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530120 · Cited by 744
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Rogers, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453640 · Cited by 579
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542
Reuther, T., Schuster, T., Mende, U., & Kübler, A. (2003) · International Journal of Oral and Maxillofacial Surgery · doi:10.1054/ijom.2002.0332 · Cited by 492
Migliorati, C. A., Schubert, M. M., Peterson, D. E., & Seneda, L. M. (2005) · Cancer · doi:10.1002/cncr.21130 · Cited by 489
Bisphosphanates and Oral Cavity Avascular Bone Necrosis
Migliorati, C. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.99.132 · Cited by 480
Choi, S. J., Cruz, J. C., Craig, F., Chung, H., Devlin, R. D., Roodman, G. D., & Alsina, M. (2000) · Blood · doi:10.1182/blood.v96.2.671 · Cited by 408
Bisphosphonate Osteochemonecrosis (Bis-Phossy Jaw): Is This Phossy Jaw of the 21st Century?
Hellstein, J. W., & Marek, C. L. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.01.010 · Cited by 270
Agarwala, S. (2005) · Rheumatology · doi:10.1093/rheumatology/keh481 · Cited by 269
Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases
Bagan, J. V., Murillo, J., Jimenez, Y., Poveda, R., Milian, M. A., Sanchis, J. M., Silvestre, F. J., & Scully, C. (2005) · Journal of Oral Pathology & Medicine · doi:10.1111/j.1600-0714.2004.00269.x · Cited by 266
Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates
Licata, A. A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e357 · Cited by 224
Mechanism of action of bisphosphonates
Reszka, A. A., & Rodan, G. A. (2003) · Current Osteoporosis Reports · doi:10.1007/s11914-003-0008-5 · Cited by 216
Bisphosphonates and osteonecrosis of the jaw
Purcell, P. M., & Boyd, I. W. (2005) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06762.x · Cited by 202
Pathogenesis of myeloma bone disease
Roodman, G. (2004) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2004.01.001 · Cited by 163
van Beek, E. R., Löwik, C. W. G. M., & Papapoulos, S. E. (2002) · Bone · doi:10.1016/s8756-3282(01)00655-x · Cited by 159
In Vivo Effects of Bisphosphonates on the Osteoclast Mevalonate Pathway
Fisher, J., Rodan, G. A., & Reszka, A. A. (2000) · Endocrinology · doi:10.1210/endo.141.12.7921 · Cited by 156
Bisphosphonates and avascular necrosis of the jaw: a possible association
Carter, G., Goss, A. N., & Doecke, C. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06761.x · Cited by 156
Effects of bisphosphonates on matrix mineralization.
Boivin, G., & Meunier, P. J. (2002) · PubMed · Cited by 117
The antitumor potential of bisphosphonates
Clézardin, P. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37420 · Cited by 84
Ten Years of Alendronate Treatment for Osteoporosis in Postmenopausal Women
Ruggiero, S. L., & Mehrotra, B. (2004) · New England Journal of Medicine · doi:10.1056/nejm200407083510218 · Cited by 40
OMURA, G. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.99.058 · Cited by 31
Bisphosphonates: new antiangiogenic molecules in cancer treatment?
Vincenzi, B., Santini, D., Rocci, L., & Tonini, G. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg194 · Cited by 29
Berenson, J. R. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.03.001 · Cited by 28
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Khan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., Reid, I. R., Ruggiero, S. L., Taguchi, A., Tetradis, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2405 · Cited by 1,353
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.009 · Cited by 1,328
Ruggiero, S. L., Dodson, T. B., Aghaloo, T., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,141
(2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.11.003 · Cited by 837
Metadata
- Authors
- Badros, A., Weikel, D., Salama, A., Goloubeva, O., Schneider, A., Rapoport, A., Fenton, R., Gahres, N., Sausville, E., Ord, R., & Meiller, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-02-20
- Volume
- 24
- Issue
- 6
- Pages
- 945-952
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166925007
- Cited by
- 593
- References
- 29
- FWCI
- 35.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.